UK’s NICE wants more ef­fec­tive­ness da­ta on Lil­ly’s tirzepatide

The Unit­ed King­dom’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence (NICE) is ask­ing Eli Lil­ly for more da­ta about tirzepatide be­fore it will rec­om­mend the type 2 di­a­betes drug’s use.

NICE said Tues­day in draft guid­ance that it has not rec­om­mend­ed the drug as a treat­ment for type 2 di­a­betes in adults. It asked Eli Lil­ly to pro­vide more da­ta to ad­dress “un­cer­tain­ties” in clin­i­cal ev­i­dence and how the drug com­pares to oth­er treat­ments for type 2 di­a­betes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER